Spots Global Cancer Trial Database for rituximab
Every month we try and update this database with for rituximab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma | NCT05575973 | Diffuse Large B... | Mitoxantrone Hy... Rituximab Lenalidomide | 60 Years - 75 Years | Huazhong University of Science and Technology | |
| Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma | NCT00005959 | Lymphoma | filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... | 18 Years - | National Cancer Institute (NCI) | |
| Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP) | NCT00450385 | Lymphoma | Rituximab Cyclophosphamid... Doxorubicin Prednisone Vincristine | 18 Years - 120 Years | University of Miami | |
| Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma | NCT00736450 | Contiguous Stag... Noncontiguous S... Stage I Adult D... Stage III Adult... Stage IV Adult ... | oblimersen sodi... rituximab cyclophosphamid... doxorubicin hyd... vincristine sul... prednisone biopsy microarray anal... immunohistochem... gene expression... cytogenetic ana... | 19 Years - | University of Nebraska | |
| Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma | NCT00055640 | Lymphoma | rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... microarray anal... | 18 Years - | Case Comprehensive Cancer Center | |
| Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma | NCT01983969 | Advanced Cancer... Lymphoma | Azacitidine Vorinostat Gemcitabine Busulfan Melphalan Dexamethasone Caphosol Glutamine Pyridoxine Rituximab | 15 Years - 65 Years | M.D. Anderson Cancer Center | |
| Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma | NCT00335140 | Lymphoma | Rituximab Cytarabine Dexamethasone Leucovorin Methotrexate Procarbazine Vincristine | 18 Years - | Eastern Cooperative Oncology Group | |
| Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma | NCT00499018 | Diffuse Large B... IPI≥2 | Rituximab Ciclofosfamide Doxorubicina Vincristina Prednisone Pegfilgrastim Mitoxantrone ARA-C Lenograstim BCNU ARA-C VP-16 ASCT Ciclofosfamide Doxorubicina Vincristina | 18 Years - 60 Years | Fondazione Italiana Linfomi - ETS | |
| Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia | NCT02877303 | B Acute Lymphob... B Lymphoblastic... | Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Laboratory Biom... Mercaptopurine Methotrexate Ofatumumab Prednisone Rituximab Vincristine Sul... | 14 Years - | M.D. Anderson Cancer Center | |
| High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas | NCT00895661 | B-cell Lymphoma Indolent B-cell... | rituximab | 18 Years - | Massachusetts General Hospital | |
| Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma | NCT00070083 | Lymphoma | oblimersen sodi... rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... | 19 Years - | National Cancer Institute (NCI) | |
| Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft | NCT04989491 | Epstein-Barr Vi... | Rituximab control group | 18 Years - | University Hospital, Strasbourg, France | |
| Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma | NCT00101010 | Lymphoma | Filgrastim Pegfilgrastim Rituximab Cyclophosphamid... Pegylated lipos... Prednisone Vincristine Sul... | 61 Years - | M.D. Anderson Cancer Center | |
| Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia | NCT00436904 | Leukemia | Alemtuzumab Rituximab | 18 Years - | Mayo Clinic | |
| Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL | NCT04404283 | Diffuse Large B... | Brentuximab ved... Rituximab Lenalidomide Placebo | 18 Years - | Seagen Inc. | |
| A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only | NCT00451178 | Lymphoma | enzastaurin rituximab cyclophosphamid... doxorubicin vincristine prednisone | 18 Years - | Eli Lilly and Company | |
| Treatment for Advanced B-Cell Lymphoma | NCT01859819 | Diffuse Large C... Burkitt's Lymph... High Grade B-ce... | Rituximab IT Cytarabine | 3 Years - 31 Years | New York Medical College | |
| Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia | NCT00324779 | Leukemia Lymphoma | rituximab | - 18 Years | National Cancer Institute (NCI) | |
| Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | NCT04361409 | Head and Neck S... | Rituximab Cisplatin Gemcitabine | 20 Years - 65 Years | China Medical University Hospital | |
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL) | NCT00100737 | Non-Hodgkin Lym... | interleukin-2 rituximab | 18 Years - | Chiron Corporation | |
| Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma | NCT04002297 | Mantle Cell Lym... | zanubrutinib bendamustine rituximab | 60 Years - | BeiGene | |
| Freiburg ZNS-NHL Study | NCT00647049 | Primary Non Hod... | methotrexate Rituximab Cytarabine Thiotepa Carmustin | 18 Years - 65 Years | University Hospital Freiburg | |
| Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma | NCT00070447 | Lymphoma | rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... yttrium Y 90 ib... | 18 Years - | National Cancer Institute (NCI) | |
| An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | NCT06047080 | Large B-Cell Ly... | Glofitamab Polatuzumab ved... Rituximab Cyclophosphamid... Doxorubicin Prednisone | 18 Years - 80 Years | Hoffmann-La Roche | |
| RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor | NCT03536039 | Lymphoma, Large... | NGR-hTNF RITUXIMAB Doxorubicin Cyclophosphamid... Vincristine Prednisone | 18 Years - 80 Years | IRCCS San Raffaele | |
| A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma | NCT01569750 | CD20-positive B... | Part 1, Cohort ... Part 1, Cohort ... Part 1, Cohort ... Part 2, Cohort ... Part 2, Cohort ... | 18 Years - | Janssen Research & Development, LLC | |
| Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia | NCT00759603 | Chronic Lymphoc... Small Lymphocyt... | Lenalidomide Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma | NCT00689169 | Lymphoma, Large... | ZBEAM (Zevalin,... ASCT Rituximab | 18 Years - 65 Years | Lymphoma Study Association | |
| Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL. | NCT01670370 | Diffuse Large B... | R-GemOx | 60 Years - | The First Affiliated Hospital with Nanjing Medical University | |
| Rituximab in Treating Patients With Hodgkin's Lymphoma | NCT00003820 | Lymphoma Hodgkin Lymphom... Nodular Lymphoc... | Rituximab | 3 Years - | Stanford University | |
| Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma | NCT00081861 | Lymphoma | Avastin Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma | NCT00055640 | Lymphoma | rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... microarray anal... | 18 Years - | Case Comprehensive Cancer Center | |
| Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma | NCT02258529 | Follicular Lymp... Small Lymphocyt... | Idelalisib Rituximab | 18 Years - | Gilead Sciences | |
| Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation | NCT01810588 | Hematologic Mal... | CliniMACS® CD34... Fludarabine Melphalan anti-thymocyte ... Rituximab Total Body Irra... Mycophenolate M... Tacrolimus | 18 Years - | Weill Medical College of Cornell University | |
| Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma | NCT01493479 | Follicular Lymp... | 90Y Ibritumomab... Rituximab | 18 Years - | The Christie NHS Foundation Trust | |
| Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer | NCT00546377 | Leukemia Lymphoma | filgrastim pegfilgrastim rituximab sargramostim cyclophosphamid... mitoxantrone hy... pentostatin fluorescence in... gene rearrangem... polymerase chai... protein express... flow cytometry biopsy | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma | NCT00144807 | Diffuse Large C... | rituximab doxorubicin cyclophosphamid... autologous stem... | 18 Years - 59 Years | Lymphoma Study Association | |
| Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. | NCT00963534 | Mantle Cell Lym... | lenalidomide, b... lenalidomide, b... | 65 Years - | Lund University Hospital | |
| Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia | NCT05453500 | B Acute Lymphob... | Bone Marrow Asp... Cyclophosphamid... Doxorubicin Etoposide Prednisone Rituximab Tafasitamab Vincristine | 18 Years - | University of Washington | |
| R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL | NCT01148446 | Elderly Patient... Diffuse Large B... | Cyclophosphamid... Cyclophosphamid... Doxorubicin Vincristine Prednisone Prednisone Epirubicin Vinblastine Rituximab G-CSF | 66 Years - 80 Years | Fondazione Italiana Linfomi - ETS | |
| Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease | NCT00176475 | Leukemia Lymphoma Multiple Myelom... | rituximab therapeutic all... | 18 Years - | Rutgers, The State University of New Jersey | |
| SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug. | NCT01295151 | Rheumatoid Arth... | Etanercept Abatacept Rituximab Adalimumab Certolizumab Pe... Infliximab Golimumab | 18 Years - | University of Leeds | |
| A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT01776840 | Mantle Cell Lym... | Bendamustine Rituximab Ibrutinib Placebo | 65 Years - | Janssen Research & Development, LLC | |
| Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | NCT04047797 | Recurrent Mantl... Refractory Mant... | Ixazomib Ixazomib Citrat... Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02) | NCT00505232 | Mantle Cell Lym... | Y-90 Ibritumoma... | 18 Years - 70 Years | CABYC | |
| Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma | NCT00003280 | Lymphoma | rituximab | 18 Years - 120 Years | Swiss Group for Clinical Cancer Research | |
| Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00193466 | Non-Hodgkins Ly... | Rituximab Fludarabine CAMPTH-1H | 18 Years - | SCRI Development Innovations, LLC | |
| Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma | NCT00032019 | Lymphoma | filgrastim rituximab cyclophosphamid... doxorubicin hyd... etoposide prednisone vincristine sul... | - | Alliance for Clinical Trials in Oncology | |
| Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00119392 | B-cell Chronic ... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Waldenström Mac... | rituximab cyclosporine fludarabine pho... mycophenolate m... yttrium Y 90 ib... peripheral bloo... allogeneic hema... total-body irra... | 18 Years - | Fred Hutchinson Cancer Center | |
| Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma | NCT00117156 | Lymphoma, Non-H... MALT Lymphoma | Fludarabine Rituximab | 18 Years - | Dana-Farber Cancer Institute | |
| A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) | NCT01539512 | Chronic Lymphoc... | Idelalisib Rituximab Placebo to matc... | 18 Years - | Gilead Sciences | |
| Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE) | NCT02316613 | Follicular Lymp... | Rituximab | 18 Years - | Hoffmann-La Roche | |
| Bortezomib Plus Rituximab for EBV+ PTLD | NCT01058239 | Post-transplant... Solid Organ Tra... Stem Cell Trans... Epstein Barr Vi... | bortezomib rituximab | 18 Years - | Massachusetts General Hospital | |
| Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma | NCT00202930 | Neuroblastoma Opsoclonus-myoc... | anti-CD20 (Ritu... | 2 Months - 18 Years | University of Pittsburgh | |
| Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma | NCT01472562 | Mantle Cell Lym... | lenalidomide rituximab | 18 Years - | Weill Medical College of Cornell University | |
| Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma | NCT00863369 | Lymphoma | rituximab bortezomib gemcitabine hyd... questionnaire a... | 18 Years - | City of Hope Medical Center | |
| Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid Arthritis | NCT06175338 | Rheumatoid Arth... | Rituximab MabThera® | 18 Years - 65 Years | Mabscale, LLC | |
| FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia | NCT00769522 | Chronic Lymphoc... | Rituximab Bendamustine Cyclophosphamid... Fludarabine | 18 Years - | German CLL Study Group | |
| Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma | NCT00017381 | Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Stage I Adult D... Stage I Adult D... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenström Mac... | rituximab cyclophosphamid... filgrastim yttrium Y 90 ib... peripheral bloo... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia | NCT00275054 | Chronic Lymphoc... | Fludarabine Cyclophosphamid... Rituximab | 18 Years - | German CLL Study Group | |
| Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A | NCT02406092 | Non-Hodgkin Lym... | Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone Fludarabine | 18 Years - 80 Years | Hoffmann-La Roche | |
| Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia | NCT00436904 | Leukemia | Alemtuzumab Rituximab | 18 Years - | Mayo Clinic | |
| Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment | NCT00881387 | Lymphoma | rituximab gemcitabine hyd... vinorelbine dit... | 18 Years - 120 Years | University of Miami | |
| Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma | NCT01381692 | Recurrent Folli... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Recurrent Walde... Refractory Foll... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal... | Bortezomib Dexamethasone Laboratory Biom... Quality-of-Life... Rituximab Temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma | NCT00980395 | Lymphoma Mantle Cell Lym... Indolent Lympho... SLL | rituximab bortezomib cladribine | 18 Years - | University of Arizona | |
| ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma | NCT00140660 | Diffuse Large C... | rituximab | 18 Years - 65 Years | Lymphoma Study Association | |
| A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT01611090 | Chronic Lymphoc... Small Lymphocyt... | Ibrutinib Bendamustine hy... Rituximab Placebo | 18 Years - | Janssen Research & Development, LLC | |
| Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies | NCT00824135 | Hematologic Mal... | Clofarabine Stem Cell Trans... OKT3 Thiotepa Melphalan Mycophenolate m... Rituximab G-CSF | - 21 Years | St. Jude Children's Research Hospital | |
| Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia | NCT03609593 | Chronic Lymphoc... | Bendamustine Venetoclax Rituximab | 18 Years - 99 Years | Columbia University | |
| Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma | NCT04884035 | Lymphoma, B-Cel... | CC-220 Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone CC-99282 Polatuzumab ved... Rituximab | 18 Years - | Celgene | |
| An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma | NCT01902862 | Lymphoma, Folli... | Bortezomib Rituximab | 18 Years - 70 Years | Janssen-Cilag G.m.b.H | |
| Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma | NCT02142049 | Diffuse Large B... Diffuse Large B... | Ibrutinib DA-EPOCH-R Lenalidomide | 18 Years - | Pharmacyclics LLC. | |
| Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma | NCT00265928 | Lymphoma | bortezomib rituximab antibody therap... biological ther... enzyme inhibito... monoclonal anti... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | NCT02576275 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Duvelisib Placebo Rituximab Bendamustine | 18 Years - | SecuraBio | |
| A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT01594229 | Non-Hodgkin's L... | ABT-199 Rituximab Bendamustine | 18 Years - 99 Years | AbbVie | |
| Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL | NCT01449344 | Mantle Cell Lym... | Rituximab High dose Ara-C Dexamethasone Bortezomib | 18 Years - | European Mantle Cell Lymphoma Network | |
| Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma | NCT00334438 | Lymphoma | rituximab bortezomib yttrium Y 90 ib... Indium 111 ibri... | 18 Years - 120 Years | UNC Lineberger Comprehensive Cancer Center | |
| Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With BL/DLBCL | NCT03958916 | Rituximab Lymphoma, Non-H... Pediatric Cance... | 1 Year - 18 Years | Sun Yat-sen University | ||
| A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL) | NCT04790903 | Lymphoma, Large... | Venetoclax Polatuzumab Ved... Rituximab Cyclophosphamid... Doxorubicin Prednisone | 18 Years - | Hoffmann-La Roche |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
